“the” focus violates the spirit of EA, and feels like a weird title for the post. “a” focus is what the correct title would be.
It’s not disinterest, it’s always been an open question and viable for prioritization. Either properties of particular peoples’ subjective EV formulas (which incorporate each of the ITN, presumably) or social contingencies (like the patents/IP culture of biotech investing feeling weird from a more software industry perspective, or something more like “people not going to enough of the same parties”, etc.) lead to it appearing to have very little EA cashflow.
I saw this comment recently asking a similar question but 9 years ago.
A friend had a draft of a givewell-style “QALYs bought by the marginal dollar spent in the longevity field” in guesstimate, but I don’t want to put his name on blast in case he thinks the draft is really bad or he didn’t get far enough. My guess is that more projects like this could meaningfully change the conversation.
“the” focus violates the spirit of EA, and feels like a weird title for the post. “a” focus is what the correct title would be.
It’s not disinterest, it’s always been an open question and viable for prioritization. Either properties of particular peoples’ subjective EV formulas (which incorporate each of the ITN, presumably) or social contingencies (like the patents/IP culture of biotech investing feeling weird from a more software industry perspective, or something more like “people not going to enough of the same parties”, etc.) lead to it appearing to have very little EA cashflow.
I saw this comment recently asking a similar question but 9 years ago.
A friend had a draft of a givewell-style “QALYs bought by the marginal dollar spent in the longevity field” in guesstimate, but I don’t want to put his name on blast in case he thinks the draft is really bad or he didn’t get far enough. My guess is that more projects like this could meaningfully change the conversation.